To visit the old Ventura website, click here.
Ventura Wealth Clients Login here
Refer and earnSupport
logosearch
Create Account
hamburger
home
breadcrumbStocks
breadcrumbLaurus Labs Limited Share Price
breadcrumbResults

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on March 31, 2025Data in Crores of INR
Revenue
₹ 1.72K+19.49% from last year
Operating profits
₹ 479.17+84.28% from last year
Net income
₹ 233.87+210.5% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Net worth4472.564110.954037.533351.192597.551769.771558.411482.641330.45856.80
Fixed assets4123.223890.013408.622652.472170.621726.341629.071480.801229.941021.03
Debt2693.082507.051971.971732.031453.201056.871035.93979.91841.751027.71
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating601.65665.69993.90911.10733.00347.42297.66342.49331.99181.97
Investing -681.72-822.42-996.06-914.34-940.99-221.13-252.88-384.15-288.67-312.20
Financing 39.28249.83-26.6430.26254.70-127.66-44.7742.24-53.61103.32

Financial ratios

Profitability ratiosinfo2
ROA4%
ROE8.3%
ROCE10.16%
EPS6.64%
Net profit margin6.38%
Operating profit margin20.35%
Dividend per share1.2%
Operational ratiosinfo2
Quick ratio0.68%
Current ratio1.22%
Interest coverage3.24%
Assets turnover0.63%
Debt to equity0.61%
Valuation ratiosinfo2
P/E ratio124.5%
P/B ratio10.03%
Dividend yield0.15%
EV/EBITDA
Laurus Labs Limited offers broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The company develops innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. It works with all the top generic pharmaceutical companies in the world. The company sells its APIs in many countries. Its major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. Continuous innovation is the lifeblood of its business. Therefore, it undertakes dedicated RD in areas that have significant growth potential. The company has commercialised various products since inception across three distinct business units: Generics API, Generics FDF and Synthesis.
personal

Grow your wealth with more research recommendations

+91